These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9107599)

  • 41. Cost-effectiveness analysis of influenza vaccination for people aged 65 and over in Japan.
    Hoshi SL; Kondo M; Honda Y; Okubo I
    Vaccine; 2007 Aug; 25(35):6511-21. PubMed ID: 17681651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices.
    Salleras L; Navas E; Domínguez A; Ibáñez D; Prat A; Garrido P; Asenjo MA; Torner N
    Vaccine; 2009 May; 27(25-26):3454-8. PubMed ID: 19200830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Influenza vaccination in health-care workers: an effective method to reduce the consequences of influenza in health care users].
    de Jong JC
    Ned Tijdschr Geneeskd; 2007 Sep; 151(39):2143-6. PubMed ID: 17957990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza cost and cost-effectiveness studies globally--a review.
    Peasah SK; Azziz-Baumgartner E; Breese J; Meltzer MI; Widdowson MA
    Vaccine; 2013 Nov; 31(46):5339-48. PubMed ID: 24055351
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The economic implications of influenza vaccination for adults with asthma.
    Trogdon JG; Nurmagambetov TA; Thompson HF
    Am J Prev Med; 2010 Nov; 39(5):403-10. PubMed ID: 20965377
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Opening and continuing the discussion on influenza vaccination timing.
    Ryan KJ; Rousculp MD
    Am J Manag Care; 2010 Aug; 16(8):628-9; author reply 629-30. PubMed ID: 20737745
    [No Abstract]   [Full Text] [Related]  

  • 47. Influenza vaccine recommendations for the 1995-96 season.
    J Ark Med Soc; 1995 Aug; 92(3):132-3. PubMed ID: 7673096
    [No Abstract]   [Full Text] [Related]  

  • 48. Influenza vaccination in healthy working adults in Russia: observational study of effectiveness and return on investment for the employer.
    At'kov OY; Azarov AV; Zhukov DA; Nicoloyannis N; Durand L
    Appl Health Econ Health Policy; 2011 Mar; 9(2):89-99. PubMed ID: 21332253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Use of excess mortality as a criterion of effectiveness in vaccination for the prevention of influenza].
    Woratz C; Sinnecker H; Woratz G; Giard W; Müller D; Hajduk F; Grimm J; Hepperle E
    Z Gesamte Hyg; 1984 Sep; 30(9):488-90. PubMed ID: 6516478
    [No Abstract]   [Full Text] [Related]  

  • 50. Influenza vaccine for healthy adults.
    Schwartz K
    J Fam Pract; 1996 Apr; 42(4):351-2. PubMed ID: 8627201
    [No Abstract]   [Full Text] [Related]  

  • 51. [Vaccination strategy in influenza].
    Niculescu IT; Zilişteanu E; Creţescu L; Oprescu E
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1975; 20(3):129-35. PubMed ID: 128101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statement on the preparation and use of inactivated influenza vaccines.
    Bull World Health Organ; 1966; 35(5):775-7. PubMed ID: 5297811
    [No Abstract]   [Full Text] [Related]  

  • 53. [Cost-effectiveness of vaccines for the prevention of seasonal influenza in different age groups: a systematic review].
    Valcárcel Nazco C; García Lorenzo B; Del Pino Sedeño T; García Pérez L; Brito García N; Linertová R; Ferrer Rodríguez J; Imaz Iglesia I; Serrano Aguilar P
    Rev Esp Salud Publica; 2018 Oct; 92():. PubMed ID: 30327454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines.
    Nichol KL
    Vaccine; 2003 May; 21(16):1769-75. PubMed ID: 12686092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influenza immunization.
    Tosolini FA; Gale AE; Rischbieth HG
    Med J Aust; 1970 Nov; 2(22):1045. PubMed ID: 5494956
    [No Abstract]   [Full Text] [Related]  

  • 56. Influenza vaccine for healthy adults?
    Patriarca PA; Strikas RA
    N Engl J Med; 1995 Oct; 333(14):933-4. PubMed ID: 7666882
    [No Abstract]   [Full Text] [Related]  

  • 57. Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination.
    Quinn E; Jit M; Newall AT
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):425-35. PubMed ID: 24734967
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccination against influenza in healthy adults.
    Carrat F
    N Engl J Med; 1996 Feb; 334(6):403; author reply 403-4. PubMed ID: 8538722
    [No Abstract]   [Full Text] [Related]  

  • 59. Results of the 1976 Rhode Island Fight-Flu Program.
    Faich GA; Martin WE
    R I Med J (1976); 1977 Nov; 60(11):519-24. PubMed ID: 270785
    [No Abstract]   [Full Text] [Related]  

  • 60. Does cost savings mean cost effective?
    Finkelstein EA; Segel JE
    Am J Prev Med; 2010 Nov; 39(5):489-90. PubMed ID: 20965391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.